LIGAND PHARMACEUTICALS INC's ticker is and the CUSIP is 53220KAF5. A total of 23 filers reported holding LIGAND PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $298,682 | 0.0% | 300,000 | 0.0% | 0.00% | – |
| Q1 2023 | $298,682 | +2.4% | 300,000 | 0.0% | 0.00% | – |
| Q4 2022 | $291,666 | -99.9% | 300,000 | 0.0% | 0.00% | – |
| Q3 2022 | $290,946,000 | -40.5% | 300,000 | -40.0% | 0.00% | – |
| Q1 2022 | $488,667,000 | -2.6% | 500,000 | 0.0% | 0.00% | – |
| Q4 2021 | $501,620,000 | +0.5% | 500,000 | 0.0% | 0.00% | – |
| Q3 2021 | $499,207,000 | +1.2% | 500,000 | 0.0% | 0.00% | – |
| Q2 2021 | $493,306,000 | -4.1% | 500,000 | 0.0% | 0.00% | – |
| Q1 2021 | $514,180,000 | -98.3% | 500,000 | -98.5% | 0.00% | -100.0% |
| Q4 2020 | $30,855,248,000 | -10.0% | 32,600,000 | -13.3% | 0.01% | -22.2% |
| Q3 2020 | $34,276,537,000 | +26.7% | 37,600,000 | +21.3% | 0.02% | +5.9% |
| Q2 2020 | $27,046,229,000 | +5.0% | 31,000,000 | 0.0% | 0.02% | -10.5% |
| Q1 2020 | $25,750,708,000 | -14.4% | 31,000,000 | -11.4% | 0.02% | +5.6% |
| Q4 2019 | $30,087,959,000 | – | 35,000,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| STEELHEAD PARTNERS LLC | 64,118,000 | $55,709,000 | 4.91% |
| SYMPHONY ASSET MANAGEMENT LLC | 9,000,000 | $7,790,000 | 1.72% |
| CANYON CAPITAL ADVISORS LLC | 65,000,000 | $56,160,000 | 1.31% |
| CAMDEN ASSET MANAGEMENT L P /CA | 44,450,000 | $38,362,000 | 1.24% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 60,954,000 | $52,832,000 | 1.02% |
| Context Capital Management, LLC | 2,350,000 | $2,028,000 | 1.02% |
| SHENKMAN CAPITAL MANAGEMENT INC | 4,160,000 | $3,622,000 | 0.47% |
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | 22,500,000 | $19,418,000 | 0.44% |
| OAKTREE CAPITAL MANAGEMENT LP | 23,903,000 | $20,688,000 | 0.39% |
| WOLVERINE ASSET MANAGEMENT LLC | 36,633,000 | $31,784,000 | 0.37% |